Company patents
VOYAGER THERAPEUTICS, INC.
VOYAGER THERAPEUTICS, INC. exhibits a concentrated patent strategy, with over half of its portfolio in Pharmaceutical Preparations (64.9%) and Peptides & Proteins (54.5%). While Peptides & Proteins showed strong growth in 2024 (+71.4%) and 2025 (+50.0%), all categories, including Therapeutic Activity (Pharma), show a significant decline in patenting activity so far in 2026, with Therapeutic Activity (Pharma) seeing a complete halt in new patents (YoY -100.0%).
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
77 US filings (since 2023) · 3 categories · 6 themes
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Patents
Showing 1-10 of 130